It began as a supply problem and evolved into a legal, regulatory, and political battle that touched hundreds of thousands of patients, a multibillion-dollar compounding pharmacy industry, two pharmaceutical giants, and the FDA itself. The story of GLP-1 drug shortages is still unfolding — and understanding it helps explain why access to these medications remains
